enGene Therapeutics Hosts Virtual KOL Event on NMIBC Market Insights

What Happened
enGene Therapeutics, Inc. announced on August 11, 2026 that it hosted a virtual key opinion leader (KOL) event to discuss emerging market research insights for non‑muscle invasive bladder cancer (NMIBC). The company filed the slide presentation from the event as Exhibit 99.1 to its Form 8‑K, and the presentation text is incorporated by reference into the filing. The report was signed by Ronald H. W. Cooper, Chief Executive Officer and President.

Key Details

• Event date: August 11, 2026 — virtual KOL event focused on NMIBC market research insights.
• Exhibit filed: Slide presentation included as Exhibit 99.1 to the Form 8‑K.
• Filing items: Reported under Item 8.01 (Other Events) and Item 9.01 (Exhibits).
• The filing did not disclose earnings, revenue, quarterly results, executive changes (CEO/CFO), mergers, acquisitions, or new financial statements.

Why It Matters
This filing gives investors access to the company’s publicly shared market perspectives and expert feedback on the NMIBC landscape, which can inform understanding of enGene’s clinical and commercial positioning. It is an informational disclosure rather than an announcement of financial results, management changes, or regulatory/clinical outcomes—investors should review Exhibit 99.1 for the detailed presentation content.